Merrell Dow Pharmaceuticals

Hoechst Marion Roussel

Merrell Pharmaceuticals, Inc.

Robert J Dinerstein

Keith A Diekema

Jeffrey S Sabol

Michael L Edwards

Winton D Jones

David M Stemerick

Fred L Ciske

The present invention describes certain alkyloxyamino-substituted fluorenones which inhibit protein kinase C, as well as pharmaceutical compositions including these compounds and methods of using these compounds to control protein kinase C activity in mammals, including humans. More specifically, the present compounds are useful for the treatment of neoplastic disease states, disorders associated with abnormal blood flow (including hypertension, ischemia, atherosclerosis, coagulation disorders), and inflammatory diseases (including immune disorders, asthma, lung fibrosis, and psoriasis).

Alkyloxyamino substituted fluorenones and their use as protein kinase-C

This invention relates to 1-aryl-3-pyridinyl-2-propene-1-ones, the use of these compounds as calcium uptake inhibitors in leukocytes and thrombocytes, and pharmaceutical compositions containing these compounds as active ingredients, and the process of their preparation.

Calcium uptake inhibitors

This invention relates to 1-phenyl-3-phenyl-2-propyne-1-ones, the use of these compounds as calcium uptake inhibitors in leukocytes and thrombocytes, and pharmaceutical compositions containing these compounds as active ingredients, and the process of their preparation.

1-phenyl-3-phenyl-2-propyne-1-ones as calcium uptake inhibitors

This invention relates to 1-phenyl-3-aryl-2-propyne-1-ones, the use of these compounds as calcium uptake inhibitors in leukocytes and thrombocytes, and pharmaceutical compositions containing these compounds as active ingredients, and the process of their preparation.

Growing community of inventors

Cincinnati, OH, United States of America

Robert J Dinerstein